FDA reportedly aims to fully approve Pfizer-BioNTech COVID-19 vaccine by early next month; Biogen’s Alzheimer drug sees little uptake; majority of Americans over 65 have received at least 1 dose of a COVID-19 vaccine.
The FDA has accelerated its timeline in order to fully approve the Pfizer-BioNTech COVID-19 by early September, according to The New York Times. Last week, President Joe Biden stated he expected a fully approved vaccine in early fall, but the FDA’s unofficial deadline is Labor Day or sooner, according to sources in the report, who hope that full approval, rather than just emergency use authorization, might inspire higher vaccination rates. Multiple universities and hospitals plan to mandate vaccination after its approval. Recent polls conducted by the Kaiser Family Foundation found that 3 of 10 unvaccinated Americans said they would be more likely to get a vaccine with full approval.
Few patients have received the controversial Alzheimer drug aducanumab (Aduhelm) yet, STAT News reported, as hospitals, health systems, and payers conduct their own reviews of the drug. Biogen, the drug’s manufacturer, has not released the number of patients treated since its FDA approval in early June, but analysts estimated in July that fewer than 100 patients have received it. The drug’s $56,000 annual cost, unknown benefit, limited availability, and delivery requirements are factors playing a role in the limited uptake.
The majority of older Americans 65 years and older are at least partially vaccinated against COVID-19, Kaiser Health News reported, with 90% partially vaccinated; some states have higher rates than others. Pennsylvania, Hawaii, and Vermont have vaccinated more than 99% of their seniors and Connecticut has vaccinated 96%, whereas West Virginia ranks last among the states with 78%. Nearly 80% of COVID-19–related deaths in the United States have been among this age group.
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Untangling Medical Debt From Credit Scores: Effects So Far and Next Steps
November 29th 2023After recent policy changes removing most medical debts from credit reports, Americans are seeing their credit scores increase, but experts warn of the need to monitor billing and collection practices for unintended consequences.
Read More
Study Validates Smartphone Analysis for Predicting Obstructive Sleep Apnea
November 29th 2023Findings show breathing sounds recorded by smartphones during sleep at home can reliably identify obstructive sleep apnea, presenting an innovative and accessible alternative to traditional in-laboratory polysomnography.
Read More